We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cell Therapeutics announced that data from a Phase I study of weekly Xyotax (paclitaxel poliglumex) given in combination with radiation for patients with esophageal or gastric cancer was published in the August edition of the American Journal of Clinical Oncology.
MethylGene has enrolled its first patient in a single-agent Phase II clinical trial of its lead compound, MGCD0103, in patients with relapsed or refractory Hodgkin's lymphoma.
Ark Therapeutics Group has announced additional results from a Phase II trial of Trinam, a gene therapy to prevent blood vessels from becoming blocked in dialysis patients who have undergone vascular access graft surgery.
YM BioSciences announced the completion of second planned safety and efficacy analysis of a Phase III trial of tesmilifene for metastatic cancer by the data safety monitoring board.
Theravance has announced results from the ATLAS I and ATLAS II trials assessing the safety and efficacy of telavancin, a rapidly bactericidal injectable antibiotic, for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria.
TolerRx announced that its lead product, TRX4, has received orphan drug designation from the FDA for the treatment of new-onset Type 1 diabetes mellitus.
Dynavax Technologies has presented new preclinical data showing that its influenza vaccine confers immunity to widely divergent viral strains and has potential as a universal flu vaccine.
MedImmune has filed an investigational new drug (IND) application with the FDA for MT103 for the treatment of patients with B-cell-derived non-Hodgkins lymphoma (NHL) not eligible for curative therapy.